Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus acidophilus TYCA06
- Development stage
- Preclinical
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus acidophilus TYCA06 is a specific probiotic strain developed by Glac Biotech, primarily utilized for its immunomodulatory effects. It is characterized by its ability to survive gastric acid and bile salts, allowing it to colonize the intestinal tract effectively. The strain's primary mechanism involves balancing the Th1/Th2 immune response; specifically, it stimulates the production of Th1 cytokines like interferon-gamma while suppressing Th2 cytokines such as interleukin-4, which leads to a decrease in allergen-specific IgE levels. This makes it a candidate for managing allergic rhinitis and other IgE-mediated allergic conditions. Additionally, research has explored its role in improving gut barrier function and potentially supporting bone health by modulating the gut-bone axis.
- Other names
- L. acidophilus TYCA06
02
Targets
IL-4 (Interleukin 4)IFNG (Interferon gamma)IgE (Immunoglobulin E)
Beyond the preview
Go deeper on Lactobacillus acidophilus TYCA06.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus acidophilus TYCA06.